Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Transfusion-dependent anemias like thalassemia lead to iron overload.
• Iron chelation therapy is crucial for managing chronic transfusions.

Purpose of the Study:

• To evaluate the efficacy of intravenous versus subcutaneous desferrioxamine (DF) in children with transfusion-dependent anemias.
• To determine optimal dosing for achieving negative iron balance.

Main Methods:

• Ten children received either intravenous or daily subcutaneous DF.
• Doses ranged up to 450 mg/kg (IV) or 110 mg/kg (SC).
• Iron balance, excretion, and liver iron levels (via biopsy) were monitored.

Main Results:

• No patients on intravenous DF achieved negative iron balance.
• Subcutaneous DF doses >60 mg/kg resulted in negative iron balance (mean 496 mg/month).
• Liver biopsies showed 40-60% iron reduction after 12-14 months of subcutaneous DF therapy.

Conclusions:

• Daily subcutaneous desferrioxamine is effective in achieving negative iron balance in anemic children.
• This chelation method prevents further iron accumulation, even with compliance issues.
• Subcutaneous DF offers a viable strategy for managing iron overload in chronically transfused pediatric patients.